$400M Proceeds from Divestitures to Fund PerkinElmer s Health Sciences Expansion | GenomeWeb

PerkinElmer plans to use its roughly $400 million in proceeds from the sale of two businesses to focus its efforts going forward primarily on the health sciences market.

The divestitures of its aerospace business and semiconductor and fluid-testing businesses also will enable the company to repay its debt, which currently stands at $270 million and has been the primary reason PerkinElmer has been relatively quiet on the acquisition front for the past few years.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.